Table 1.
General Population Model Inputs
| Model parameter | Base value | Low value | High value |
|---|---|---|---|
| Fidaxomicin | |||
| Initial treatment failure rate5,11,16 | 12.06% | 9.05% | 15.08% |
| Rate of first CDAD recurrence5,11,16 | 14.14% | 10.61% | 17.68% |
| Rate of second CDAD recurrence17 | 20.30% | 15.23% | 25.38% |
| Daily drug acquisition cost | $235 | ||
| Vancomycin | |||
| Initial treatment failure rate5,11,16 | 13.78% | 10.34% | 17.23% |
| Rate of first CDAD recurrence5,11,16 | 26.02% | 19.52% | 32.53% |
| Rate of second CDAD recurrence17 | 32.30% | 24.23% | 40.38% |
| Daily drug acquisition cost, 125 mg | $20 | – | – |
| Daily drug acquisition cost, 250 mg | $40 | – | – |
| Nondrug specific | |||
| Cost of additional hospital days in cases with treatment failure4 | $5573 | $4179 | $6966 |
| Attributable hospitalization cost of initial CDAD4 | $11,145 | $8359 | $13,931 |
| Attributable hospitalization cost of recurrent CDAD18 | $12,627 | $9703 | $15,838 |
| No. of days of drug therapy received in hospital19,20 | 6.00 | 4.50 | 7.50 |
| % of patients with recurrent CDAD who are rehospitalized21 | 51.60 | 39.40 | 63.80 |
CDAD = Clostridium difficile–associated diarrhea.